GlaxoSmithKline PLC (ADR) (NYSE:GSK) is on the verge of leapfrogging Sanofi SA (ADR) (NYSE:SNY) in the meningococcal vaccine market in terms of sales.
Keep Reading →
June 8 - News, Stock Analysis
Deerfield Management, a healthcare-focused fund managed by James E.
Keep Reading →
December 11 - Hedge Funds, News
Based on the fact that hedge funds have collectively under-performed the market for several years, it would be easy to assume that their stock picks simply aren't very good.
Keep Reading →
November 27 - Hedge Funds, News
When it comes to 11 Biggest Generic Drug Companies in the World one can say that the list hasn’t changed a great deal over the years.
Keep Reading →
June 27 - Lists
Hedge funds have started submitting their 13F filings with the SEC, offering other investors a chance to look at their equity holdings as of the end of the first quarter.
Keep Reading →
April 24 - Hedge Funds, News
GlaxoSmithKline plc (ADR) (NYSE:GSK) remains committed to eradicating the deadly virus which has already claimed more than 2,000 lives in Western Africa and is considered as the...
Keep Reading →
September 8 - News
Companies around the world, who do business in China were keeping a close watch on the trial of the British company investigator, Peter Humphrey, and his American wife and...
Keep Reading →
August 10 - News
In an interview with Bloomberg, Odile Rundquist, who is an analyst at Helvea, discusses on the second Qtr.
Keep Reading →
July 18 - Earnings Report, News
Rio Tinto plc (ADR) (NYSE:RIO), the world’s second-biggest mining company, is now seeing iron ore trading close to $100 per metric ton.
Keep Reading →
July 17 - News
Warren Buffett’s Berkshire Hathaway, in its latest 13F, revealed its equity portfolio held at the end of the fourth quarter of 2013.
Keep Reading →
February 14 - Hedge Funds, News
Relvar Ellipta: Over the past few days, research-based pharmaceutical GlaxoSmithKline plc (ADR) (NYSE:GSK) and biopharmaceutical company Theravance Inc (NASDAQ:THRX)’s Relvar...
Keep Reading →
September 23 - News
To me, flu season is a lot like Christmas; there's a defined time period when we expect it to occur, yet it seems to appear earlier and earlier every year.
Keep Reading →
September 23 - News
Chemical nerve agents have garnered much media coverage recently, but receiving less attention are the companies involved in the development of countermeasures to these and biological...
Keep Reading →
September 23 - News
There is perhaps nothing scarier than a cancer diagnosis.
Keep Reading →
September 17 - News
The small patient pool for medullary thyroid cancer, or MTC, isn't going to move the needle for a large pharmaceutical company. But Exelixis, Inc.
Keep Reading →
September 17 - News
There's no question that America is addicted to caffeine and sugar.
Keep Reading →
September 17 - News
GlaxoSmithKline plc (ADR) (NYSE:GSK) and its partner Theravance Inc (NASDAQ:THRX) recently scored a second victory in their quest to treat chronic obstructive pulmonary disease...
Keep Reading →
September 16 - News
There are plenty of biotech companies that put all of their eggs in one basket these days.
Keep Reading →
September 16 - News
Looking for the best-performing sector in this year's big market rally? It may just be the biotech sector, which has erupted with astronomical gains in 2013.
Keep Reading →
September 16 - News
In a way, stocks go through seasons like the weather. Sometimes they spring forth, sometimes they're hot like summer, sometimes they're dormant and cold like winter.
Keep Reading →
September 16 - News
With the SPDR S&P Biotech Index up 40% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector.
Keep Reading →
September 15 - News
There hasn't been a dull moment for investors of Theravance Inc (NASDAQ:THRX) since the company submitted an NDA for COPD/asthma drug BREO before the Food and Drug Administration...
Keep Reading →
September 12 - News
I follow quite a lot of companies, so the usefulness of a watchlist to me cannot be overstated.
Keep Reading →
September 12 - News
It hasn't been a fun month to be an investor in clinical-stage biotech ChemoCentryx Inc (NASDAQ:CCXI).
Keep Reading →
September 11 - News
China has loomed large in health care headlines recently, due to the GlaxoSmithKline plc (ADR) (NYSE:GSK) scandal that erupted in July.
Keep Reading →
September 11 - News
I know it's like comparing apples and oranges, but humor me for a moment.
Keep Reading →
September 11 - News
Trading of biopharmaceutical company Theravance Inc (NASDAQ:THRX) was halted on Tuesday. A major decision hung in the balance as the U.S.
Keep Reading →
September 11 - News
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis...
Keep Reading →
September 10 - News
China's not losing importance in the eyes of investors, despite the world's second-largest economy's slump this year.
Keep Reading →
September 10 - News
Emerging-market stocks have been butchered over the past few months amid fears that the Federal Reserve will begin winding down its bond-buying program.
Keep Reading →
September 10 - News
With second-quarter earnings season now in the books and about a month to go before third-quarter earnings kicks off, biotech savvy investors are in for a treat this week with...
Keep Reading →
September 9 - News
With the SPDR S&P Biotech Index up 38% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector.
Keep Reading →
September 9 - News
At the moment, there are dozens of gauges investors can use to track Mr. Market. A pair of the most under-the-radar are hedge fund and insider trading movement.
Keep Reading →
September 6 - News
Over the past decade, the Food and Drug Administration has taken multiple steps to improve the process by which drugs are developed and eventually brought to market.
Keep Reading →
September 4 - News
In the financial world, there are many methods market participants can use to track the equity markets.
Keep Reading →
September 3 - News
Now, according to many investors, hedge funds are seen as overrated, outdated investment tools of a period lost to current times.
Keep Reading →
August 30 - News
Drugs fail their clinical trials for all kinds of reasons. Sometimes, it's related to efficacy; sometimes, it's safety related.
Keep Reading →
August 30 - News
In a previous article, I speculated on the race to develop a Duchenne muscular dystrophy, or DMD, drug and who might win it.
Keep Reading →
August 29 - News
A small section of the total Crohn's Disease) patient population is resistant to standard treatment options.
Keep Reading →
August 29 - News
In the 21st century investor’s toolkit, there are dozens of methods market participants can use to monitor the equity markets.
Keep Reading →
August 29 - News
ViiV Healthcare -- a joint venture by Pfizer Inc.
Keep Reading →
August 28 - News
At the same time, the pharmaceutical industry isn't without its share of risks.
Keep Reading →
August 28 - News
Shares of Perrigo Company (NYSE:PRGO), one of the world's largest health care suppliers, slid with the broader market on Aug.
Keep Reading →
August 27 - News
Duchenne muscular dystrophy, or DMD, is a muscle-wasting disease caused by a genetic mutation in the dystrophin gene -- the largest gene on the X chromosome -- which affects one...
Keep Reading →
August 27 - News
While many investors worried about the Nasdaq's three-hour shutdown this week, shareholders of a few stocks probably wished it wouldn't have come back up.
Keep Reading →
August 26 - News
Shares of small biotech ChemoCentryx Inc (NASDAQ:CCXI) collapsed by 44% in early trading on Friday before paring the losses somewhat.
Keep Reading →
August 23 - Dividend Stocks, News
HIV, the virus that causes AIDS, has become one of the world's most devastating diseases since it was first recognized more than three decades ago.
Keep Reading →
August 23 - News
To the average investor, there are plenty of gauges investors can use to track Mr. Market. Some of the most useful are hedge fund and insider trading interest.
Keep Reading →
August 22 - News
In the eyes of many of your peers, hedge funds are perceived as useless, outdated financial tools of a forgotten age.
Keep Reading →
August 22 - News
